Evidence map›Paper›PMID 34979995›Full record

ArticleBMC cancer2022

Serum apolipoprotein B to apolipoprotein A-I ratio is an independent predictor of liver metastasis from locally advanced rectal cancer in patients receiving neoadjuvant chemoradiotherapy plus surgery.

Chen Chen, Wei Yi, Zhi-Fan Zeng, Qiao-Xuan Wang, Wu Jiang, Yuan-Hong Gao, Hui Chang

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Apolipoproteins: New players in cancers.Frontiers in pharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Chen Chen *Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Wei Yi *Department of Radiation Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zhi-Fan ZengDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Qiao-Xuan WangDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Wu JiangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yuan-Hong GaoDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. gaoyh@sysucc.org.cn.
Hui ChangDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. changhui@sysucc.org.cn.
Sun Yat-sen University · CNSun Yat-sen University Cancer Center · CNFirst Affiliated Hospital of Guangzhou Medical University · CNState Key Laboratory of Oncology in South China

Funding

Guangdong Basic and Applied Basic Research Foundation, China 2020A1515010037Guangdong Basic and Applied Basic Research Foundation, China 2020A1515011286
6 · The paper itself

Abstract

backgroundThe ratio of serum apolipoprotein B (apoB) to apolipoprotein A-I (apoAI) had been reported as a prognostic factor in colorectal cancer. This retrospective study aimed to assess the implication of apoB-to-apoAI ratio in predicting liver metastasis from rectal cancer (RC).

methodsThe clinical data of 599 locally advanced RC patients treated with chemoradiotherapy followed by surgery were reviewed. Serum apoAI, apoB and apoB-to-apoAI ratio were analyzed for their correlation with the liver-metastasis-free, other-metastasis-free and overall survivals, together with the pretreatment and postsurgical pathoclinical features of the patients. Univariate and multivariate survival analyses were realized through the Kaplan-Meier approach and Cox model, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for independent predictors.

resultsCarbohydrate antigen 19 - 9 ≥ 26.3 U/ml, apoB-to-apoAI ratio ≥ 0.63, tumor regression grade 5 - 3, pT4 and pN + stage emerged as independent predictors of poorer liver-metastasis-free survival. The hazard ratios were 1.656 (95% CI, 1.094-2.506), 1.919 (95% CI, 1.174-3.145), 1.686 (95% CI, 1.053-2.703), 1.890 (95% CI, 1.110-3.226) and 2.012 (95% CI, 1.314-2.077), respectively. Except apoB-to-apoAI ratio, the other 4 factors were also independent predictors of poorer other-metastasis-free and overall survivals. And the independent predictors of poorer overall survival also included age ≥ 67 years old, distance to anal verge < 5 cm.

conclusionsSerum apoB-to-apoAI ratio could be used as a biomarker for prediction of liver metastasis risk in locally advanced RC.

Indexed as

AdolescentAdultAgedAntigens, Tumor-Associated, CarbohydrateApolipoprotein A-IApolipoproteins BBiomarkers, TumorCombined Modality TherapyFemaleHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyPostoperative PeriodAntigens, Tumor-Associated, CarbohydrateAPOA1 protein, humanApolipoprotein A-IApolipoproteins BBiomarkers, Tumorcarbohydrate antigen 199, humanApolipoproteinLiver metastasisRectal cancerSurvival

Identifiers

PMID34979995
PMCPMC8722169
OpenAlexW4205475805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.